SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce its upcoming presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer's Disease even in the Presence of Co-Morbid Pathologies” at the Alzheimer's Association International Conference (AAIC), July 31 – Aug. 4, 2022, in San Diego.
“Over 50% of people with AD have additional co-morbid pathologies of dementia, such as multi-infarct dementia, Parkinson’s disease or Frontal Lobe Dementia,” says Dr. Daniel Alkon, chief scientific advisor, SDx. “At the AAIC, we will present specific data evaluating the ability of the Morphometric Imaging (MI) assay in DISCERN to identify AD in people diagnosed with dementia, even in the presence of other co-morbid pathologies at autopsy.”
Dr. Alkon further explains that DISCERN™ is a diagnostic skin test comprised of three assays that assess the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD. The DISCERN AD Biomarkers also assess factors that regulate amyloid plaque and tau formation, hallmarks of AD at autopsy.
DISCERN has demonstrated >95% specificity and sensitivity in identifying AD through long duration blind, autopsy-validated clinical trials with reference to the National Institutes of Health criteria that define AD at autopsy.
“DISCERN is an important breakthrough for the AD community because there are currently no FDA-approved tests that are highly sensitive and highly specific for AD in early dementia,” says Frank Amato, CEO and president, SDx. “While previously published data further validated with autopsies demonstrate both high specificity and high sensitivity, this will be the first data assessing the ability of the MI assay to accurately distinguish AD in people with comorbid dementias.”
AAIC attracts the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community to share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for AD.
For more information, visit us at booth #322 at the AAIC.
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The Company offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: info@synapsdx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005059/en/
Contacts
Media:
Caroline Chambers
CPR Communications
cchambers@cpronline.com
201.641.1911 x 21
